{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T12:44:53Z","timestamp":1787834693298,"version":"build-2784847793"},"reference-count":19,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Risk &amp; Safety in Medicine"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Stevens-Johnson syndrome (SJS), a rare and severe toxic epidermal necrolysis, is reported here for the first time at the University Hospital Center of Libreville (CHUL), suspected to be related to fluconazole administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To inform clinicians about the risks associated with fluconazole in immunocompromised patients and the related healthcare expenses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>The patient is a 39-year-old immunocompromised woman who received a single dose 400\u00a0mg of fluconazole. Two weeks later, she developed a rash affecting approximately 10 % of her body surface, confirmed as SJS. During clinical examinations, no signs of infection, such as fever, dizziness, or chills, were present, suggesting a drug-induced SJS reaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Causality assessment assigned an intrinsic score of I6 and extrinsic score of B2 according to the French method, and a probable temporal relationship was confirmed using the world Health Organization (WHO) method. The ALDEN scale identified fluconazole as the probable cause (score = 4). No additional risk factors were identified (SCORTEN = 0, predicted mortality: 3.2 %). Economically, the total direct medical cost of hospitalization amounted to 605,700 CFA francs, or 923.38 \u20ac.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Immunocompromised HIV-positive patients treated with 400\u00a0mg of fluconazole are likely to develop SJS and incur costs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09246479251325475","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T04:54:22Z","timestamp":1741928062000},"page":"134-140","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Fluconazole-induced Stevens-Johnson syndrome at Libreville University Hospital - Gabon: A case report"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8330-7476","authenticated-orcid":false,"given":"Pierre Constant","family":"Ntoutoume Nzoghe","sequence":"first","affiliation":[{"name":"Pharmaco-epidemiology and Pharmacoeconomics Research Team, Pharmacology and Toxicology Laboratory, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8796-3837","authenticated-orcid":false,"given":"Rim","family":"Lakhmiri","sequence":"additional","affiliation":[{"name":"Pharmaco-epidemiology and Pharmacoeconomics Research Team, Pharmacology and Toxicology Laboratory, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Coniquet","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Center of Libreville, Libreville, Gabon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landry","family":"Missounga","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Center of Libreville, Libreville, Gabon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Ntsame","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University Hospital Center of Libreville, Libreville, Gabon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahia","family":"Cherrah","sequence":"additional","affiliation":[{"name":"Pharmaco-epidemiology and Pharmacoeconomics Research Team, Pharmacology and Toxicology Laboratory, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8599-7257","authenticated-orcid":false,"given":"Samira","family":"Serragui","sequence":"additional","affiliation":[{"name":"Pharmaco-epidemiology and Pharmacoeconomics Research Team, Pharmacology and Toxicology Laboratory, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"e_1_3_5_2_2","article-title":"Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN or Lyell syndrome)","author":"Benedetti J","year":"2024","unstructured":"Benedetti J. Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN or Lyell syndrome). Harvard Medical School 2024.","journal-title":"Harvard Medical School"},{"key":"e_1_3_5_3_2","unstructured":"Hamish S Houssaini AS Ismaili N et al. Lyell syndrome and Stevens-Johnson syndrome: retrospective study of 30 cases. 2022; 35(2): 116\u2013124."},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.9.697.34072"},{"key":"e_1_3_5_5_2","first-page":"1225","volume-title":"Good man and Gilman\u2019s The Pharmacological Basis of Therapeutics","author":"Bennett JE","year":"2006","unstructured":"Bennett JE. Antimicrobial agents \u2013 antifungal agents. In: Brunton LL, Lazo JS, Parker KL (eds). Good man and Gilman\u2019s The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2006, pp. 1225\u20131241."},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/1757-1626-2-9071"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2000.01119.x"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/428486a"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.04.048"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2011073"},{"key":"e_1_3_5_11_2","unstructured":"World Health Organization. Monitoring the safety of medicines. 2000."},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90112-3"},{"issue":"12","key":"e_1_3_5_13_2","first-page":"WD01","article-title":"Fluconazole induced Stevens-Johnson syndrome leading to the diagnosis of HIV infection","volume":"13","author":"Prafulla Kumar S","year":"2019","unstructured":"Prafulla Kumar S, Soumya S, Konchok D, et al. Fluconazole induced Stevens-Johnson syndrome leading to the diagnosis of HIV infection. J Clin Diagn Res 2019; 13(12): WD01.","journal-title":"J Clin Diagn Res"},{"key":"e_1_3_5_14_2","volume-title":"Textbook of adverse drug reactions","author":"Rawlins MD","year":"1977","unstructured":"Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM (ed). Textbook of adverse drug reactions. Oxford: Oxford University Press, 1977."},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.5958\/0974-360X.2019.00639.5"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.252"},{"key":"e_1_3_5_17_2","unstructured":"Available from. https:\/\/www.sfdermato.org\/upload\/groupe\/bloc\/file\/score-alden-pdf.pdf ( accessed 29 November 2024)."},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00061.x"},{"key":"e_1_3_5_19_2","unstructured":"Available from. https:\/\/www.sfdermato.org\/upload\/recommandations\/ald-31-pnds-sjs-lyell-web.pdf (accessed 29 November 2024)."},{"key":"e_1_3_5_20_2","unstructured":"Africabizinfo.com. https:\/\/www.africabizinfo.com\/GA\/office-pharmaceutique-national-opn-04-35-79-29 (accessed 30 October 2023)."}],"container-title":["International Journal of Risk &amp; Safety in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479251325475","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09246479251325475","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479251325475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:45:45Z","timestamp":1777509945000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09246479251325475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1177\/09246479251325475"],"URL":"https:\/\/doi.org\/10.1177\/09246479251325475","relation":{},"ISSN":["0924-6479","1878-6847"],"issn-type":[{"value":"0924-6479","type":"print"},{"value":"1878-6847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]}}}